Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis
Proteasome inhibitors are able to efficiently induce apoptosis in many tumor cells while leaving quiescent, untransformed cells largely unharmed. Here we investigated the further enhancement of proteasome inhibitor-mediated apoptosis induction in Bcr-Abl positive K562 CML cells by simultaneous treatment with different histone deacetylase inhibitors (HDIs). Combining proteasome and HDIs resulted in rapid hyperacetylation of histone H3 and accumulation of polyubiquitinated proteins and the synergistic induction of apoptosis. Apoptosis induction was associated with caspase 8, 3 and 9 activation, Bid processing, destruction of the mitochondrial membrane potential, cleavage of PARP and lamin B and extensive DNA fragmentation. The pan-caspase inhibitor Z-VAD-FMK and the caspase-8 inhibitor Z-IETD-FMK could inhibit K562 cell apoptosis. Apoptosis was also delayed by overexpression of Bcl-xL, as well as by crmA, a known inhibitor of caspases 1 and 8. Caspase 8 activity could still be detected in the presence of ectopic Bcl-xL, but not in crmA transfected cells. The most striking anti-apoptotic effect though was obtained by the translational inhibitor cycloheximide, which abolished caspase 8 processing, blocked Bid cleavage and maintained the mitochondrial transmembrane potential. Apoptosis by the combination treatment occurred independently from CD95/Fas receptor stimulation. These results demonstrated that transcriptional activation by HDIs combined with proteasome inhibitor mediated posttranslational stabilization of protein(s) results in significantly enhanced CML apoptosis which was striktly dependent on uninterrupted protein synthesis.
Keywordsapoptosis Bcr-Abl chemoresistance histone deacetylase inhibitor leukemia proteasome
Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev
(2): 373–428.PubMedGoogle Scholar
Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol
(6): 628–634.CrossRefPubMedGoogle Scholar
Almond JB, Cohen GM. The proteasome: A novel target for cancer chemotherapy. Leukemia
(4): 433–443.CrossRefPubMedGoogle Scholar
Drexler HC, Pebler S. Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors. Cell Death Differ
(3): 290–301.CrossRefPubMedGoogle Scholar
An B, Goldfarb RH, Siman R, Dou Q. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ
(12): 1062–1075.CrossRefPubMedGoogle Scholar
Richardson G, Barlogie B, Berenson J, et al.
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med
(26): 2609–2617.PubMedGoogle Scholar
Aghajanian C, Soignet S, Dizon DS, et al.
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res
(8): 2505–2511.PubMedGoogle Scholar
Orlowski RZ, Stinchcombe TE, Mitchell BS, et al.
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol
, 2002; 20
(22): 4420–4427.CrossRefPubMedGoogle Scholar
Herrmann JL, Briones Jr. F, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene
(22): 2889–2899.CrossRefPubMedGoogle Scholar
Drexler HCA. Activation of the cell death program by inhibition of proteasome function. Proc Nat Acad Sci USA
(3): 855–860.CrossRefPubMedGoogle Scholar
Chandra J, Niemer I, Gilbreath J, et al.
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood
, 1998; 92
(11): 4220–4229.PubMedGoogle Scholar
Delic J, Masdehors P, Omura S, et al.
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to Tnf-alpha-initiated apoptosis. Brit J Cancer
, 1998; 77
(7): 1103–1107.PubMedGoogle Scholar
Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res
(9): 2429–2434.PubMedGoogle Scholar
Bedi A, Barber JP, Bedi GC, et al.
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood
(3): 1148–1158.PubMedGoogle Scholar
McGahon A, Bissonnette R, Schmitt M. et al.
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood
(5): 1179–1187.PubMedGoogle Scholar
Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem
(50): 39223–39230.CrossRefPubMedGoogle Scholar
Druker BJ, Sawyers CL, Kantarjian H, et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med
(14): 1038–1042.CrossRefPubMedGoogle Scholar
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med
(14): 1031–1037.CrossRefPubMedGoogle Scholar
Ottmann OG, Druker BJ, Sawyers CL, et al.
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood
, 2002; 100
(6): 1965–1971.CrossRefPubMedGoogle Scholar
Gorre ME, Mohammed M, Ellwood K, et al.
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science
(5531): 876–880.CrossRefPubMedGoogle Scholar
le Coutre P, Tassi E, Varella-Garcia M, et al.
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood
, 2000; 95
(5): 1758–1766.PubMedGoogle Scholar
Weisberg E, Griffin JD, Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood
, 2000; 95
(11): 3498–3505.PubMedGoogle Scholar
Dou QP, McGuire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther
(2): 781–790.PubMedGoogle Scholar
Naujokat C, Sezer O, Zinke H, et al.
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol
(4): 221–236.CrossRefPubMedGoogle Scholar
Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays
(8): 615–626.CrossRefPubMedGoogle Scholar
He LZ, Guidez F, Tribioli C, et al.
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet
(2): 126–135.CrossRefPubMedGoogle Scholar
Lin RJ, Nagy L, Inoue S, et al.
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature
(6669): 811–814.CrossRefPubMedGoogle Scholar
Grignani F, De Matteis S, Nervi C, et al.
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature
(6669): 815–818.CrossRefPubMedGoogle Scholar
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov
(4): 287–299.CrossRefPubMedGoogle Scholar
Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst
(15): 1210–1216.CrossRefPubMedGoogle Scholar
Bernhard D, Skvortsov S, Tinhofer I, et al.
Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ
(10): 1014–1021.CrossRefPubMedGoogle Scholar
Klisovic MI, Maghraby EA, Parthun MR, et al.
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia
(2): 350–358.CrossRefPubMedGoogle Scholar
Kurz EU, Wilson SE, Leader KB, et al.
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther
(2): 121–131.PubMedGoogle Scholar
Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K, Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood
(8): 3236–3239.CrossRefPubMedGoogle Scholar
Mitsiades CS, Mitsiades NS, McMullan CJ, et al.
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA
2004; 101(2): 540–545.CrossRefPubMedGoogle Scholar
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth
(2): 271–279.CrossRefGoogle Scholar
Yin L, Laevsky G, Giardina C, Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem
(48): 44641–44646.CrossRefPubMedGoogle Scholar
Hitomi J, Katayama T, Eguchi Y, et al.
Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol
(3): 347–356.CrossRefPubMedGoogle Scholar
Saleh M, Vaillancourt JP, Graham RK, et al.
Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature
(6987): 75–79.CrossRefPubMedGoogle Scholar
Glick RD, Swendeman SL, Coffey DC, et al.
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res
(17): 4392–4399.PubMedGoogle Scholar
Kwon SH, Ahn SH, Kim YK, et al.
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem
(3): 2073–2080.CrossRefPubMedGoogle Scholar
Vrana JA, Grant S. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood
, 2001; 97
(7): 2105–2114.CrossRefPubMedGoogle Scholar
Chen WJ, Lin JK. Induction of G1 arrest and apoptosis in human Jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1 and Bax proteins. J Biol Chem
Di Bacco AM, Cotter TG. p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br J Haematol
(3): 588–597.CrossRefPubMedGoogle Scholar
Nimmanapalli R, Fuino L, Bali P, et al.
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res
(16): 5126–5135.PubMedGoogle Scholar
Garcia-Calvo M, Peterson EP, Leiting B, et al.
Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem
(49): 32608–32613.CrossRefPubMedGoogle Scholar
McGahon AJ, Nishioka WK, Martin SJ, et al.
Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem
, 1995; 270
(38): 22625–22631.CrossRefPubMedGoogle Scholar
Kim K. Proteasome inhibitors sensitize human vascular smooth muscle cells to Fas (CD95)-mediated death. Biochem Biophys Res Commun
(2): 305–310.CrossRefPubMedGoogle Scholar
Tani E, Kitagawa H, Ikemoto H, Matsumoto T. Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells. FEBS Lett
(1–2): 53–58.CrossRefPubMedGoogle Scholar
Giuliano M, Lauricella M, Calvaruso G, et al.
The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res
(21): 5586–5595.PubMedGoogle Scholar
Yu C, Rahmani M, Conrad D, et al.
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood
, 2003; 102
(10): 3765–3774.CrossRefPubMedGoogle Scholar
Tan S, Seow TK, Liang RC, et al.
Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer
, 2002; 98
(4): 523–531.CrossRefPubMedGoogle Scholar
Faucheu C, Diu A, Chan AW, et al.
A novel human protease similar to the interleukin-1 beta converting enzyme induces apoptosis in transfected cells. Embo J
, 1995; 14
(9): 1914–1922.PubMedGoogle Scholar
Luciano F, Jacquel A, Colosetti P, et al.
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene
(43): 6785–6793.CrossRefPubMedGoogle Scholar
Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem
(21): 18811–18816.CrossRefGoogle Scholar
Hideshima T, Mitsiades C, Akiyama M, et al.
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood
(4): 1530–1534.CrossRefPubMedGoogle Scholar
Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene
, 2003; 22
(46): 7108–7122.CrossRefPubMedGoogle Scholar
Chauhan D, Li G, Podar K, et al.
Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood
(8): 3158–3166.CrossRefPubMedGoogle Scholar
Bogner C, Ringshausen I, Schneller F, et al.
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol
, 2003; 122
(2): 260–268.CrossRefPubMedGoogle Scholar
Chen L, Smith L, Wang Z, Smith JB. Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: Any single lysine or lysine pair of the small subunit is sufficient for ubiquitination. Mol Pharmacol
, 2003; 64
(2): 334–345.CrossRefPubMedGoogle Scholar
Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther
(12): 1273–1284.PubMedGoogle Scholar
Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol
(8): 1537–1545.CrossRefPubMedGoogle Scholar
Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia
(7): 1331–1343.CrossRefPubMedGoogle Scholar
Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp Cell Res
(1): 31–47.CrossRefPubMedGoogle Scholar
Maecker HL, Koumenis C, Giaccia AJ. p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res
(16): 4638–4644.PubMedGoogle Scholar
Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell
(2): 139–148.CrossRefPubMedGoogle Scholar
Travers KJ, Patil CK, Wodicka L, et al.
Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell
(3): 249–258.PubMedGoogle Scholar
Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest
(10): 1389–1398.CrossRefPubMedGoogle Scholar
Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell
(5): 767–776.CrossRefPubMedGoogle Scholar
Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol
(22): 9695–9704.CrossRefPubMedGoogle Scholar
© Springer Science + Business Media, Inc. 2005